Atara Biotherapeutics Inc., of Brisbane, Calif., said it dosed the first patient in a phase I study of STM 434, an Activin inhibitor, in patients with ovarian cancer and other solid tumors. The study is designed to assess the safety, tolerability and efficacy of STM 434 as a single therapy and in combination with liposomal doxorubicin.